Furrukh Muhammad, Kumar Shiyam, Zahid Khawaja F, Al-Shamly Hanan S, Al-Jabri Zainab A, Burney Ikram A, Al-Moundhri Mansour S
Department of Medicine, Shifa College of Medicine, Islamabad, Pakistan.
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Sultan Qaboos Univ Med J. 2017 Aug;17(3):e301-e308. doi: 10.18295/squmj.2017.17.03.007. Epub 2017 Oct 10.
The incidence of lung cancer in Oman has shown a gradual but definitive increase since 2002. This study aimed to evaluate the demographic and epidemiological characteristics and survival outcomes of patients with non-small-cell lung cancer (NSCLC) at a university hospital in Oman.
This study was conducted from January to June 2016. A retrospective analysis was performed of consecutive patients diagnosed with NSCLC presenting to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between March 2000 and December 2015. Clinical features at presentation and prognostic and predictive markers were reviewed. Kaplan-Meir estimates were used to determine relapse-free survival, progression-free survival (PFS) and overall survival (OS).
A total of 104 patients presented to SQUH during the study period. The median age at diagnosis was 64 years. Overall, 62 patients (59.6%) had adenocarcinomas. Only 12 patients (11.5%) presented in the early stages (I or II) of the disease and the majority of patients had an Eastern Cooperative Oncology Group performance status of 1 (27.9%) or 2 (26.0%). The prevalence of mutations was 27.9%. The median PFS for patients with advanced disease (stages III or IV) was five months and the median OS for all patients was seven months. After five years, 50.0%, 60.0%, 10.0% and 8.0% of patients with disease stages I, II, III and IV, respectively, were alive.
Patients with NSCLC in Oman were found to present at an advanced stage. However, patient outcomes were similar to those reported in the USA.
自2002年以来,阿曼肺癌的发病率呈逐步但明确的上升趋势。本研究旨在评估阿曼一家大学医院非小细胞肺癌(NSCLC)患者的人口统计学和流行病学特征以及生存结果。
本研究于2016年1月至6月进行。对2000年3月至2015年12月期间在阿曼马斯喀特苏丹卡布斯大学医院(SQUH)就诊并被诊断为NSCLC的连续患者进行回顾性分析。回顾了就诊时的临床特征以及预后和预测标志物。采用Kaplan-Meir估计法确定无复发生存期、无进展生存期(PFS)和总生存期(OS)。
在研究期间,共有104例患者到SQUH就诊。诊断时的中位年龄为64岁。总体而言,62例患者(59.6%)患有腺癌。只有12例患者(11.5%)在疾病早期(I期或II期)就诊,大多数患者的东部肿瘤协作组体能状态为1(27.9%)或2(26.0%)。突变的发生率为27.9%。晚期疾病(III期或IV期)患者的中位PFS为5个月,所有患者的中位OS为7个月。5年后,疾病I期、II期、III期和IV期的患者分别有50.0%、60.0%、10.0%和8.0%存活。
发现阿曼的NSCLC患者就诊时处于晚期。然而,患者的预后与美国报道的相似。